Lung Cancer Clinical Trial

Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

Summary

To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer

View Full Description

Full Description

To determine the maximal tolerated dose (MTD) and toxicities of Pemetrexed (Alimta) when administered concurrently with carboplatin and thoracic radiation therapy.

To determine, qualitatively, the occurrence of local tumor responses identified with this regimen.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Unresectable Stage II, IIIB or IV non small cell lung cancer. Evaluable disease on planning CT scan Zubrod 0-1 Weight loss equal to or less than 10% 3 months prior to diagnosis FEV1 greater than 1000cc Adequate hematologic, renal and hepatic functions

Exclusion Criteria:

Small cell cancer Stage I non small cell cancer Prior chemotherapy or thoracic or lower neck radiatio therapy

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

18

Study ID:

NCT00330044

Recruitment Status:

Completed

Sponsor:

Sidney Kimmel Cancer Center at Thomas Jefferson University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Thomas Jefferson University Hospital
Philadelphia Pennsylvania, 19107, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

18

Study ID:

NCT00330044

Recruitment Status:

Completed

Sponsor:


Sidney Kimmel Cancer Center at Thomas Jefferson University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider